Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
GRAIL, LLC (GRAL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: GRAL (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Analysis of Past Performance
Type Stock | Historic Profit 48.41% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 850.77M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1472743 | Beta - | 52 Weeks Range 12.33 - 63.99 | Updated Date 04/2/2025 |
52 Weeks Range 12.33 - 63.99 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -63.54 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -301.88% |
Management Effectiveness
Return on Assets (TTM) -13.19% | Return on Equity (TTM) -65.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 155441674 | Price to Sales(TTM) 6.77 |
Enterprise Value 155441674 | Price to Sales(TTM) 6.77 | ||
Enterprise Value to Revenue 1.24 | Enterprise Value to EBITDA - | Shares Outstanding 33895200 | Shares Floating 22501359 |
Shares Outstanding 33895200 | Shares Floating 22501359 | ||
Percent Insiders 13.64 | Percent Institutions 78.91 |
Analyst Ratings
Rating 3 | Target Price 16 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
GRAIL, LLC
Company Overview
History and Background
GRAIL, LLC was founded in 2016 by Illumina, Inc. with the goal of detecting cancer early, when it can be cured. It focused on developing a multi-cancer early detection (MCED) blood test. In 2021, Illumina reacquired GRAIL, resulting in ongoing regulatory scrutiny.
Core Business Areas
- Early Cancer Detection: GRAIL develops and commercializes blood tests for early cancer detection, aiming to identify multiple cancer types through a single test.
Leadership and Structure
GRAIL operates as a division of Illumina. The leadership team consists of executives overseeing research, development, commercialization, and regulatory affairs related to early cancer detection.
Top Products and Market Share
Key Offerings
- Galleri: Galleri is a multi-cancer early detection (MCED) blood test designed to detect a shared cancer signal from over 50 types of cancer, including many that are not commonly screened for today. Exact market share is still evolving but Galleri has seen over 100,000 tests ordered. Competitors include Exact Sciences and Freenome, Guardant Health
Market Dynamics
Industry Overview
The cancer diagnostics market is rapidly evolving, driven by advances in genomics and liquid biopsy technology. There is increasing demand for early detection methods to improve patient outcomes.
Positioning
GRAIL aims to be a leader in the MCED market with its Galleri test, leveraging its technology and backing from Illumina. The position is currently under regulatory constraints.
Total Addressable Market (TAM)
The total addressable market for cancer diagnostics and early detection is estimated to be worth tens of billions of dollars annually. GRAIL's position is focused on capturing a significant share of the early detection segment with its Galleri test.
Upturn SWOT Analysis
Strengths
- Proprietary technology for multi-cancer early detection
- Strong backing and resources from Illumina
- Potential to revolutionize cancer screening
- Demonstrated clinical validity and utility
- First-mover advantage in multi-cancer screening
Weaknesses
- High cost of the Galleri test
- Need for further clinical validation in diverse populations
- Regulatory hurdles related to Illumina's acquisition
- Competition from other diagnostic companies
- Limited insurance coverage
Opportunities
- Expanding insurance coverage for Galleri
- Further developing the Galleri test for improved accuracy
- Partnering with healthcare providers for wider adoption
- International expansion
- Leveraging data for personalized cancer screening
Threats
- Competition from other MCED tests
- Regulatory challenges to Illumina/GRAIL deal
- Uncertainty about long-term clinical benefits
- Potential for false positives and patient anxiety
- Erosion of market share due to late entrants
Competitors and Market Share
Key Competitors
- EXAS
- GH
- NVTA
- THMO
- ONCO
Competitive Landscape
GRAIL's advantage lies in its technology and Illumina's resources. Its disadvantages include regulatory hurdles and competition from established diagnostic companies such as Exact Sciences (EXAS), Guardant Health (GH), and others.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: GRAIL's historical growth is characterized by significant R&D investment and clinical validation efforts. Commercial sales of the Galleri test are relatively recent.
Future Projections: Future growth depends on successful commercialization of Galleri, expanding insurance coverage, and navigating regulatory challenges. Analyst estimates are incorporated into Illumina's overall financial projections.
Recent Initiatives: GRAIL has been focused on expanding clinical validation studies, securing regulatory approvals, and partnering with healthcare providers to offer the Galleri test.
Summary
GRAIL, LLC holds promise in early cancer detection with Galleri, leveraging Illumina's backing. Regulatory challenges and competition pose risks. Success hinges on clinical validation, insurance coverage, and strategic partnerships. Recent initiatives focus on expanding market presence and demonstrating clinical value. Market adoption is key for sustainable growth.
Similar Companies
DHR
Danaher Corporation
DHR
Danaher Corporation
EXAS
EXACT Sciences Corporation
EXAS
EXACT Sciences Corporation
GH
Guardant Health Inc
GH
Guardant Health Inc
ONCO
Onconetix Inc
ONCO
Onconetix Inc
THMO
Thermogenesis Holdings Inc
THMO
Thermogenesis Holdings Inc
Sources and Disclaimers
Data Sources:
- Illumina Investor Relations
- SEC Filings
- Company Press Releases
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and based on available data. Investment decisions should be made based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GRAIL, LLC
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2024-06-25 | CEO & Director Mr. Robert P. Ragusa | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1000 | Website https://grail.com |
Full time employees 1000 | Website https://grail.com | ||
GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally. It provides Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company offers development services including support for ongoing clinical studies, pilot testing, research, and therapy development. It also develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.